# Acousia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acousia-therapeutics

- Industry: Biotechnology
- Headquarters: Germany
- Website: www.acousia.com
- Total disclosed funding: $14M
- Latest round: Series B (May 14, 2018)
- Investors on record: 6

## About

Based in Tübingen, Germany, and founded in 2012 by Hubert Löwenheim and Boehringer Ingelheim, Acousia Therapeutics GmbH, a.k.a. Acousia Therapeutics is a biotechnology company that focuses on finding and developing novel compounds that can be used to prevent and treat patients suffering from sensorineural hearing loss (SNHL). In January 2024, Acousia Therapeutics GmbH raised venture funding from Esperante Ventures.

The company’s first clinical study of ACOU085 for age-related hearing loss is underway following approval from the German Federal Institute for Drugs and Medical Devices. 

The company plans to use its proceeds from January 2024 funding to continue the clinical development of its products.

## Funding rounds

- Series B, May 14, 2018, $12M — KfW Banking Group, LBBW Venture Capital, Creathor Ventures, Boehringer Ingelheim Venture, Bregua Corporation
- Series A, Dec 14, 2016, $2.6M — KfW Banking Group, Boehringer Ingelheim Venture, Axxam S.p.A.

## Investors

- KfW Banking Group — Series A, Series B
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A, Series B
- Axxam S.p.A. — Series A
- LBBW Venture Capital (https://capitalatlas.ai/funds/lbbw-venture-capital) — Series B
- Creathor Ventures (https://capitalatlas.ai/funds/creathor-ventures) — Series B
- Bregua Corporation — Series B